Editorial Podcasts

Eric Turbiville, author of the recently published book “The Perfect Leadership Triad: How Top Executives Maximize Productivity through People, Coaching, and Performance," a 25-year pharma veteran, credentialed executive coach, and director of mentoring for the Southwest region of the Healthcare Businesswomen’s Association says there are three leadership principles can help executives through tumultuous times.

Kurt Orlofski, CEO of Pharmaceutical Associates Inc., discusses what the pharmaceutical supply chain might look like post COVID-19, and how companies can prepare for that.

Jim and Cindy DiBiasi, co-founders of 3D Communications, talk about how to prepare for virtual high-level meetings, such as important regulatory presentations and keynote addresses, in the wake of COVID-19.

Tim Walbert, CEO of Horizon Therapeutics, shares his unique perspective on managing a company through COVID-19, in light of the fact that he himself is immunocompromised.

Janice Kranz, co-founder of Eikonizo Therapeutics, bring us up to date on how targeting tau to fight Alzheimer’s and other neurodegenerative diseases is making waves in the CNS space.

Dr. Jonathan Gertler, CEO of Back Bay Life Science Advisors, and Dr. Stephan Gauldie, Senior Vice President of Back Bay, talk about the new guidelines set forth by FDA in regard to gene therapy, and what those new parameters mean for pharma and biotech.

Senior Editor, Elaine Quilici interviews Pratap Khedkar, managing principal of ZS Associates. Pratap talks about pharma’s scenario planning amid COVID-19 as it looks to settle into a new normal.

Lew Bender, founder of Intensity Therapeutics and the inventor of Intensity’s DfuseRx platform technology, discusses the technology that allows the company’s therapeutic products to be injected directly into solid tumors, this innovative process successfully kills tumors and activates an immune response to shut down cancer cells throughout the body.

Kathrin Jansen, Senior Vice President and Head of Vaccine Research and Development at Pfizer, talks about the challenges of creating a new maternal vaccine for respiratory syncytial virus, also known as RSV, currently being administered to pregnant women in trials, in the hopes of protecting their infants.

Barbara Ryan, founder of Barbara Ryan Advisors, a member of PharmExec’s editorial advisory board, and the founder of Fabulous Pharma Females discusses the strong community she’s built providing women the opportunity to connect with each other and reinforce their shared commitment to one another.

Dr. Eric von Hofe, Chief Scientific Officer at NuGenerex Immuno-Oncology talks about the recent outbreak of Wuhan coronavirus around the world and how biotechs and pharma are jumping in to help find a solution.

Yuval Cohen, CEO of Corbus Pharmaceuticals, talks about cannabinoids, the differences between natural and synthetic products, and how biotechs and pharma are using them to treat disease today.

Mike Strazzella, head of federal government relations for Buchanan Ingersoll & Rooney, talks about pricing issues in the pharmaceutical industry, the challenges he encounters, and what he believes needs to change in the industry going forward.

Pharm Exec speaks with Nigel Breakwell and Ben Randal, co-founders of Dot I/O Health. Nigel and Ben talk about how they’re using data science in the health and life sciences industries to help clients navigate emerging markets.

Pharm Exec editors discuss the themes chosen for the January issue focusing on industry trends for the coming year.

Heather Monte, Director of Operations for DirectRx, talks about the specialty pharma’s new Patient Scorecard, which aims to identify and improve adherence by reporting patients’ prescription patterns to doctors.

Julia Owens, co-founder and CEO of Millendo Therapeutics talks about how to keep a company on the path to success, even when there are bumps in the road. She discusses the value of focusing on strengths and how that is currently working for Millendo in the endocrine space.

William Lewis, chairman and CEO of Insmed talks about the approval of the company’s drug Arikayce through the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs, some ideas that he spoke about on the recent NORD panel about innovative and ethical partnerships, and Insmed’s pipeline and progress.

Pharm Exec editors discuss the articles they focused on for the November Annual Pipeline Report.

Sven Klingemann, research director at Reputation Institute talks about pharma’s negative public perception and what the industry can do to improve it.

Pharm Exec editors interview Mark Glickman, Chief Commercial Officer of Esperion Therapeutics. Glickman discusses the overall cholesterol-lowering space and how it’s planning to add a new therapeutic option for patients, what it means to establish a new therapy in a statin-dominated market, market research approaches, and more.

Jeannine Lynch, senior director at BioMarin Pharmaceuticals, oversees patient access services and talks with editors about the patient journey in regard to receiving therapies, how to engage with patients more effectively, and where she sees the pharma industry in terms of patient engagement and patient centricity.

Janssen’s company group chairman of Europe, Middle East, and Africa operations, Kris Sterkens speaks with Pharm Exec editors. Kris talks about his finance background, global pricing issues, and challenges and opportunities for EMEA biopharma breaking into the US market.

Apellis’ CEO and co-founder, Dr. Cedric Francois talks with Pharm Exec editors about his journey from clinical work to creating biotech startups, which has included research, clinical work, and the launch of two startups.

Christine Sakdalan, Head of Franchise Strategy and Customer Solutions at Janssen Pharmaceutical talks with Pharm Exec editors about how patient-centricity fuels innovation, the difference between patient and customer centricity, and educational programs that need to be implemented for patients, providers, and payers.

Pharm Exec editors sit down with Mark Velleca, CEO of G1 Therapeutics. In this episode, Mark talks about how he differentiates himself in the oncology field, why he considers G1 Therapeutics an "old school company," and about the North Carolina biotech landscape.

Pharm Exec editors share insights into what they've been working on this summer for the June, July, and August issues; plus a sneak peek into what's coming in September!